Drugs Made In America Acquisition Corp.
DMAA- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0002028614
No open-market purchases or sales by Drugs Made In America Acquisition Corp. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $124.9M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Drugs Made In America Acquisition Corp. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 39 | 39 | 0 |
| Shares | 22.6M | 22.9M | +229.2K (+1.0%) |
| Value | $232.1M | $237.3M | +$5.27M (+2.3%) |
New holders (6)
Institutions that held Drugs Made In America Acquisition Corp. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Highbridge Capital Management LLC | 1,323,351 | $13.9M | 0.88% |
| Meteora Capital, LLC | 380,299 | $3.99M | 0.29% |
| RLH Capital LLC | 316,551 | $3.32M | 1.69% |
| Sona Asset Management (US) LLC | 162,795 | $1.71M | 0.07% |
| BNP Paribas Arbitrage, SA | 14,737 | $154.4K | 0.00% |
| Citadel Advisors LLC | 10,476 | $110.0K | 0.00% |
Sold out (6)
Institutions that held Drugs Made In America Acquisition Corp. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Mercuria Capital Strategies, LLC | 750,000 | $7.51M |
| J. Goldman & Co LP | 500,000 | $5.19M |
| Boothbay Fund Management, LLC | 346,154 | $3.59M |
| Bulldog Investors, LLP | 130,264 | $1.35M |
| UBS Group AG | 38,159 | $395.7K |
| Logan Stone Capital, LLC | 10,900 | $113.1K |